Cellectis (CLLS) News Today $1.27 -0.03 (-2.31%) Closing price 04:00 PM EasternExtended Trading$1.27 0.00 (-0.08%) As of 07:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 Time Period Cellectis (NASDAQ:CLLS) Lowered to Hold Rating by StockNews.comMarch 21, 2025 | americanbankingnews.comCellectis (NASDAQ:CLLS) Rating Lowered to "Hold" at StockNews.comStockNews.com downgraded Cellectis from a "buy" rating to a "hold" rating in a research report on Wednesday.March 20, 2025 | marketbeat.comReviewing Cellectis (NASDAQ:CLLS) & Achilles Therapeutics (NASDAQ:ACHL)March 20, 2025 | americanbankingnews.comCellectis (NASDAQ:CLLS) Announces Earnings ResultsCellectis (NASDAQ:CLLS - Get Free Report) announced its earnings results on Thursday. The biotechnology company reported ($0.16) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.06 by ($0.22). Cellectis had a negative return on equity of 74.55% and a negative net margin of 234.39%. The company had revenue of $33.22 million for the quarter, compared to analyst estimates of $5.90 million.March 16, 2025 | marketbeat.comCellectis Reports 2024 Financial Results and Strategic AdvancesMarch 15, 2025 | tipranks.comCellectis S.A. Earnings Call Highlights Strategic GrowthMarch 14, 2025 | tipranks.comCellectis S.A. (CLLS) Q4 2024 Earnings Call TranscriptMarch 14, 2025 | seekingalpha.comBarclays Sticks to Their Buy Rating for Cellectis SA (CLLS)March 14, 2025 | markets.businessinsider.comCellectis Reports Financial Results for the Fourth Quarter and Full Year 2024 and Provides a Business UpdateMarch 14, 2025 | markets.businessinsider.comCellectis reports Q4 EPS (64c) vs (17c) last yearMarch 14, 2025 | markets.businessinsider.comCellectis Reports Financial Results for the Fourth Quarter and Full Year 2024 and Provides a Business UpdateMarch 13, 2025 | globenewswire.comCellectis to Report Fourth Quarter and Full Year 2024 Financial Results on March 13, 2025March 7, 2025 | globenewswire.comCellectis (NASDAQ:CLLS) Share Price Crosses Below 50-Day Moving Average - Here's WhyCellectis (NASDAQ:CLLS) Stock Crosses Below Fifty Day Moving Average - Here's WhyFebruary 28, 2025 | marketbeat.comStockNews.com Begins Coverage on Cellectis (NASDAQ:CLLS)StockNews.com began coverage on shares of Cellectis in a research report on Thursday. They issued a "buy" rating on the stock.February 27, 2025 | marketbeat.comCellectis Presents ‘Smart CAR T’ Strategy to Enhance Efficacy Against Solid Tumors at AACR-IO 2025February 24, 2025 | markets.businessinsider.comCellectis Presents ‘Smart CAR T' Strategy to Enhance Efficacy Against Solid Tumors at AACR-IO 2025February 24, 2025 | globenewswire.comBaillie Gifford & Co. Trims Stock Position in Cellectis S.A. (NASDAQ:CLLS)Baillie Gifford & Co. decreased its holdings in Cellectis S.A. (NASDAQ:CLLS - Free Report) by 58.1% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 290,429 shares of the biotechnology company's stock afterFebruary 19, 2025 | marketbeat.comCellectis (NASDAQ:CLLS) Now Covered by Analysts at StockNews.comStockNews.com began coverage on shares of Cellectis in a report on Wednesday. They set a "buy" rating for the company.February 19, 2025 | marketbeat.comCellectis S.A. (NASDAQ:CLLS) Short Interest Up 34.0% in JanuaryCellectis S.A. (NASDAQ:CLLS - Get Free Report) was the recipient of a large growth in short interest in January. As of January 31st, there was short interest totalling 221,300 shares, a growth of 34.0% from the January 15th total of 165,200 shares. Based on an average daily trading volume, of 139,900 shares, the days-to-cover ratio is presently 1.6 days.February 15, 2025 | marketbeat.comCellectis S.A. (NASDAQ:CLLS) Short Interest Down 18.8% in JanuaryCellectis S.A. (NASDAQ:CLLS - Get Free Report) was the recipient of a large decrease in short interest in the month of January. As of January 15th, there was short interest totalling 165,200 shares, a decrease of 18.8% from the December 31st total of 203,500 shares. Based on an average trading volume of 139,000 shares, the short-interest ratio is currently 1.2 days.February 1, 2025 | marketbeat.comStockNews.com Initiates Coverage on Cellectis (NASDAQ:CLLS)StockNews.com initiated coverage on Cellectis in a report on Friday. They issued a "buy" rating for the company.January 24, 2025 | marketbeat.comShort Interest in Cellectis S.A. (NASDAQ:CLLS) Expands By 59.7%Cellectis S.A. (NASDAQ:CLLS - Get Free Report) saw a large growth in short interest in December. As of December 31st, there was short interest totalling 203,500 shares, a growth of 59.7% from the December 15th total of 127,400 shares. Based on an average daily trading volume, of 108,400 shares, the short-interest ratio is presently 1.9 days.January 17, 2025 | marketbeat.comEuropean Equities Traded in the US as American Depositary Receipts Rise ThursdayJanuary 16, 2025 | msn.comCellectis files to sell 44M ordinary shares for holdersJanuary 16, 2025 | markets.businessinsider.comCellectis S.A announces potential resale of up to 44M sharesJanuary 16, 2025 | msn.comCellectis (NASDAQ:CLLS) Coverage Initiated by Analysts at StockNews.comStockNews.com began coverage on shares of Cellectis in a report on Thursday. They set a "sell" rating for the company.January 16, 2025 | marketbeat.comCellectis (NASDAQ:CLLS) Now Covered by StockNews.comStockNews.com began coverage on shares of Cellectis in a research report on Wednesday. They issued a "sell" rating for the company.January 8, 2025 | marketbeat.comDo Options Traders Know Something About Cellectis (CLLS) Stock We Don't?January 7, 2025 | msn.comCellectis S.A. (NASDAQ:CLLS) Short Interest Down 6.5% in NovemberCellectis S.A. (NASDAQ:CLLS - Get Free Report) saw a large decline in short interest in November. As of November 30th, there was short interest totalling 131,400 shares, a decline of 6.5% from the November 15th total of 140,500 shares. Based on an average trading volume of 56,100 shares, the short-interest ratio is currently 2.3 days.December 16, 2024 | marketbeat.comCellectis Secures Final Tranche of EIB Credit Facility for CAR T-Cell DevelopmentDecember 12, 2024 | markets.businessinsider.comCellectis: Poised To Start Answering Questions In 2025December 12, 2024 | seekingalpha.comCellectis announces the drawdown of the third tranche of €5 million under the credit facility agreement entered with the European Investment Bank (EIB)December 10, 2024 | globenewswire.comCellectis (NASDAQ:CLLS) Earns Sell Rating from Analysts at StockNews.comStockNews.com began coverage on shares of Cellectis in a research report on Friday. They issued a "sell" rating for the company.November 29, 2024 | marketbeat.comPromising Partnership and Pipeline Propel Cellectis SA to a Buy RatingNovember 8, 2024 | markets.businessinsider.comCellectis S.A. (NASDAQ:CLLS) Q3 2024 Earnings Call TranscriptNovember 8, 2024 | msn.comCellectis SA: Strategic Advancements and Financial Strengths Justify Buy RatingNovember 7, 2024 | markets.businessinsider.comCellectis price target lowered to $5 from $7 at BarclaysNovember 7, 2024 | markets.businessinsider.comCellectis Presents Multiple Strategies to Enhance CAR T-cell Efficacy in Solid Tumors at the SITC Annual MeetingNovember 5, 2024 | globenewswire.comCellectis S.A. (CLLS) Q3 2024 Earnings Call TranscriptNovember 5, 2024 | seekingalpha.comBarclays Has Lowered Expectations for Cellectis (NASDAQ:CLLS) Stock PriceBarclays decreased their price objective on shares of Cellectis from $7.00 to $5.00 and set an "overweight" rating for the company in a report on Tuesday.November 5, 2024 | marketbeat.comCellectis Provides Business Updates and Financial Results for Third Quarter 2024November 4, 2024 | globenewswire.comCellectis SA to Unveil Q3 2024 Financial ResultsNovember 1, 2024 | markets.businessinsider.comCellectis (CLLS) Scheduled to Post Earnings on MondayCellectis (NASDAQ:CLLS) will be releasing earnings after the market closes on Monday, November 4, Zacks reports.October 31, 2024 | marketbeat.comCellectis to Report Third Quarter 2024 Financial Results on November 4, 2024October 30, 2024 | globenewswire.comCellectis (NASDAQ:CLLS) Receives New Coverage from Analysts at StockNews.comStockNews.com started coverage on Cellectis in a research report on Monday. They set a "sell" rating on the stock.October 28, 2024 | marketbeat.comCellectis Presents New Gene-Editing BreakthroughsOctober 22, 2024 | msn.comCellectis to Present Data on TALE-Base Editors and Non-Viral Gene Therapy at the ESGCT 31st Annual CongressOctober 22, 2024 | finance.yahoo.comCellectis to Present Data on TALE-Base Editors and Non-Viral Gene Therapy at the ESGCT 31st Annual CongressOctober 22, 2024 | globenewswire.comCellectis (NASDAQ:CLLS) Research Coverage Started at StockNews.comStockNews.com started coverage on Cellectis in a research report on Sunday. They issued a "sell" rating for the company.October 20, 2024 | marketbeat.comCellectis (NASDAQ:CLLS) Stock Crosses Below 200-Day Moving Average of $2.41Cellectis (NASDAQ:CLLS) Stock Price Passes Below Two Hundred Day Moving Average of $2.41September 26, 2024 | marketbeat.com Remove Ads Get Cellectis News Delivered to You Automatically Sign up to receive the latest news and ratings for CLLS and its competitors with MarketBeat's FREE daily newsletter. Email Address CLLS Media Mentions By Week CLLS Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CLLS News Sentiment▼0.770.78▲Average Medical News Sentiment CLLS News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CLLS Articles This Week▼11▲CLLS Articles Average Week Remove Ads Get Cellectis News Delivered to You Automatically Sign up to receive the latest news and ratings for CLLS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies ANNX News SEPN News CMPS News DSGN News AVIR News CADL News CRVS News IMMP News MBX News SLRN News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CLLS) was last updated on 3/28/2025 by MarketBeat.com Staff From Our PartnersElon Warns: Exec Order 14024 Targets DollarExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | SponsoredA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredElon Musk is helping print “new gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredMost gold “analysts” aren’t really gold analysts… [watch out]People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | SponsoredDo this Before Elon's Reveal on April 23rdElon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but...Brownstone Research | SponsoredYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cellectis S.A. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cellectis With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy CLLS Stock Free CLLS Stock Alerts